Cart
sales@molnova.com
PHI-101
CAS No. 2127107-15-5
PHI-101( —— )
Catalog No. M37298 CAS No. 2127107-15-5
PHI-101 is an orally available and selective checkpoint kinase 2 (Chk2) inhibitor for the study of refractory acute myelogenous leukemia (AML) and ovarian cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 278 | Get Quote |
|
| 5MG | 436 | Get Quote |
|
| 10MG | 702 | Get Quote |
|
| 25MG | 1362 | Get Quote |
|
| 50MG | 2190 | Get Quote |
|
| 100MG | 3411 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePHI-101
-
NoteResearch use only, not for human use.
-
Brief DescriptionPHI-101 is an orally available and selective checkpoint kinase 2 (Chk2) inhibitor for the study of refractory acute myelogenous leukemia (AML) and ovarian cancer.
-
DescriptionPHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetChk
-
RecptorChk
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2127107-15-5
-
Formula Weight386.44
-
Molecular FormulaC19H19FN4O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (258.77 mM; Ultrasonic )
-
SMILESN(C(N)=O)C1=C(C(N[C@H]2CCCNC2)=O)SC(C#CC3=CC(F)=CC=C3)=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nam K Y, et al. PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia[J]. Blood, 2020, 136: 28.
molnova catalog
related products
-
GDC0575 monohydrochl...
GDC-0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2?nM. GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis.
-
4-Demethyldeoxypodop...
4-Demethyldeoxypodophyllotoxin, an aryl tetrahydronaphthalenyl lignan analog from the roots of Podophyllum peltatum, has anticancer activity and modulates the Chk-2 signaling pathway in MCF-7 breast cancer cells.
-
PV-1019
A potent, ATP-competitive and highly selective Chk2 inhibitor with IC50 of 138 nM.
